CION Ameerpet
A brain tumour diagnosis in a child is frightening. Ependymoma is treatable, and outcomes are strongest with complete surgery and precise radiation. CION coordinates every step under our paediatric team.
An ependymoma is a tumour that grows from ependymal cells — the thin lining of the fluid-filled spaces (ventricles) inside the brain and the central canal of the spinal cord. In children, it forms most often at the back of the brain (the posterior fossa), where it can block the normal flow of cerebrospinal fluid. Less commonly it appears in the spinal cord or the upper part of the brain.
Childhood ependymoma (also called paediatric ependymoma) is one of the more common brain tumours seen in children. It is a serious diagnosis, but it is treatable — and outcomes have improved with modern surgery, precise radiation, and molecular testing that pinpoints the exact tumour subtype. Because it is a childhood condition, your child's overall care is managed under CION's pediatric cancer team, part of our wider brain tumour programme.
The 2021 World Health Organization classification of tumours reclassified ependymoma by location and DNA-methylation profile, not by appearance alone. This is why two children with an "ependymoma" can have very different outlooks — and why molecular subtyping, recommended in NCCN and SIOP-Europe (EANO-linked) guidance, now guides every treatment plan.
Most childhood headaches, tummy upsets, and clumsy phases have ordinary, harmless causes — viral illness, growth, tiredness, or a passing bug. A brain tumour is a rare reason. What matters is the pattern: a symptom that is new, persistent, and steadily getting worse deserves a doctor's review.
Because a posterior-fossa ependymoma can block fluid flow and raise pressure inside the skull, the clues often cluster together:
Red flags that need prompt review: a first-ever seizure; one-sided weakness or new eye-movement problems; or the combination of morning headache with vomiting and unsteadiness. These do not mean your child has a tumour — but they should be checked without delay. Speak to a CION paediatric specialist if you are worried.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you have just received an ependymoma diagnosis or want to understand what the molecular subtype means, CION's paediatric team is here — with same-week appointments and a free written second opinion.
Getting the diagnosis right — and complete — shapes everything that follows. CION coordinates the imaging, laboratory tests, and pathology review, working with accredited neurosurgical partners for the tissue sample.
Because ependymoma can shed cells that travel in the cerebrospinal fluid and settle elsewhere, the scan must cover the brain and the entire spine with contrast — not the brain alone. This shows the tumour's exact location, its size, its relationship to critical structures, and whether there is any spinal spread. In infants, a scan may be done under gentle sedation to keep them still.
A sample of the cerebrospinal fluid may be examined for tumour cells. The diagnosis is confirmed on tissue removed at surgery. That tissue then undergoes molecular and DNA-methylation testing, which — under the WHO 2021 system — identifies the precise ependymoma subtype and grade. This is not a formality: the subtype is one of the strongest signals of how the tumour will behave and how intensively it needs to be treated.
Treatment is planned by a paediatric tumour board and tailored to your child's age, the tumour's location, and its molecular subtype. The pathway usually has three parts.
What CION delivers directly: imaging and diagnosis, molecular testing, radiation therapy, systemic (chemo) therapy where needed, steroid and seizure management, and supportive and rehabilitation care. Neurosurgery is coordinated with accredited partners. Read more on childhood brain tumours and the transactional brain tumour treatment page.
For ependymoma, how completely the tumour is removed at surgery is consistently reported in paediatric studies and NCCN guidance as one of the most powerful factors in a child's outcome. This is why a specialist centre and an experienced neurosurgical partner matter so much — and why a second opinion before surgery can be worthwhile.
Every family wants to know "what does this mean for my child?" — and the honest answer is that it depends heavily on the individual tumour: the child's age, where the tumour is, its molecular subtype, and how completely it was removed. Published paediatric series and NCCN / SIOP-Europe guidance report 5-year survival broadly in the range of about 50% to 75% when the tumour is fully removed and radiation is given, with poorer results when tumour is left behind.
These are population ranges, framed to help you understand the landscape — not a prediction for any single child, and never a guarantee. We do not quote a single CION survival number for brain tumours. Your paediatric oncologist will explain what your child's specific subtype means for their care.
Ependymoma can return, most often at the original site, so children have regular surveillance MRI scans of the brain and spine for several years. Follow-up also watches for late effects on hormones, hearing, learning, and growth, particularly after radiation to a young brain. CION's paediatric survivorship plan brings together endocrine checks, neuro-cognitive support, physiotherapy, and school liaison, so your child is supported well beyond active treatment.
Childhood brain tumours are treated differently from adult tumours — with careful attention to a growing brain and the long life ahead. That is why ependymoma in children sits within CION's dedicated paediatric programme.
To arrange a free consultation and a written second opinion, request a callback or call 18002028726 — our team will connect you to the right paediatric specialist.
Get a free written second opinion from CION's paediatric tumour board — especially valuable before surgery, or if molecular subtyping hasn't yet been arranged for your child.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Ependymoma is a tumour that grows from ependymal cells — the thin lining of the fluid-filled spaces (ventricles) of the brain and the central canal of the spinal cord. In children it forms most often at the back of the brain (the posterior fossa), where it can block the flow of cerebrospinal fluid. It can also appear in the spinal cord or the upper brain. Ependymoma is one of the more common brain tumours of childhood, and outcomes have improved with modern surgery and radiation. At CION, childhood brain tumours are managed under our pediatric cancer team, working with accredited neurosurgical partners.
Signs depend on where the tumour is and the child's age. A posterior-fossa ependymoma often blocks fluid flow, so early clues are morning headaches, vomiting (especially on waking), and unsteadiness or clumsiness. In babies who cannot describe symptoms, look for a rapidly enlarging head, a bulging soft spot, irritability, or feeding problems. Spinal ependymomas can cause back pain, leg weakness, or changes in bladder or bowel control. Most of these symptoms have common, harmless causes — but a symptom that is new, persistent, and getting worse, or a first-ever seizure, should be checked by a doctor promptly.
Diagnosis starts with an MRI of the brain and the whole spine with contrast, because ependymoma can seed along the cerebrospinal fluid pathways. A sample of the cerebrospinal fluid may be examined for tumour cells. The diagnosis is confirmed on tissue removed at surgery, and modern classification (WHO 2021) uses molecular and DNA-methylation testing to identify the exact subtype and grade — which strongly guides treatment and prognosis. CION arranges the imaging, molecular testing, and pathology review, coordinating the neurosurgical step with accredited partner centres.
The cornerstone is maximal safe surgical removal of the tumour — the amount removed is one of the strongest predictors of outcome. This surgery is delivered by accredited neurosurgical partners; CION coordinates the pathway. Focused radiation therapy to the tumour bed usually follows, and modern conformal techniques (IMRT/IGRT) help protect the developing brain. Chemotherapy has a smaller, situation-specific role — for example in very young children or when surgery must be delayed. Every child's plan is set by a paediatric tumour board. Learn more on our childhood brain tumours and pediatric cancer pages.
Outcomes vary a great deal by the child's age, tumour location, molecular subtype, and — above all — how completely the tumour is removed. Published paediatric series and NCCN and SIOP-Europe guidance report 5-year survival broadly in the range of about 50% to 75% for children whose tumour is completely removed and treated with radiation, with poorer results when tumour is left behind. These are population ranges, not a promise for any one child. We never quote a single CION survival figure for brain tumours — your paediatric oncologist will explain what the specific subtype means for your child.
Yes. Ependymoma can come back, most often at the original site, so children have regular surveillance MRI scans of the brain and spine for years after treatment. Follow-up also watches for late effects on hormones, hearing, learning, and growth — especially after radiation to a young brain. CION's pediatric cancer team builds a survivorship plan that includes endocrine checks, neuro-cognitive support, physiotherapy, and school liaison, so the whole family is supported well beyond the end of active treatment.
CION delivers the paediatric oncology backbone directly: imaging and diagnosis, molecular testing, radiation therapy, systemic (chemo) therapy where needed, steroid and seizure management, and supportive and rehabilitation care. The neurosurgery itself is coordinated with accredited neurosurgical partners experienced in children — we do not perform brain surgery in-house. Because childhood ependymoma is a paediatric condition, your child's overall care is managed under CION's pediatric cancer hub. Call to arrange a free consultation and second opinion.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.